Scarica l'app Stockscreener
33.59
3.46%
-1.2202
Precedente Chiudi:
$34.81
Aprire:
$34.7
Volume 24 ore:
242.27K
Relative Volume:
0.26
Capitalizzazione di mercato:
$3.80B
Reddito:
$14.09M
Utile/perdita netta:
$-176.94M
Rapporto P/E:
-15.62
EPS:
-2.15
Flusso di cassa netto:
$-141.24M
1 W Prestazione:
+6.18%
1M Prestazione:
-6.52%
6M Prestazione:
+40.14%
1 anno Prestazione:
+44.85%
Intervallo 1D:
$33.52
$34.95
Intervallo di 1 settimana:
$30.17
$34.95
Portata 52W:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Confronta NAMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
33.55 | 3.95B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-25 | Iniziato | Wells Fargo | Overweight |
| 2025-07-17 | Iniziato | Goldman | Neutral |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
Update Report: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trends2025 Market WrapUp & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Assessing NewAmsterdam Pharma Co: Insights From 5 Financial Analysts - Benzinga
Risks Report: Does HONDW stock have upside surprise potentialEarnings Overview Summary & Accurate Buy Signal Alerts - baoquankhu1.vn
Responsive Playbooks and the NAMSW Inflection - Stock Traders Daily
Aug Intraday: Will NewAmsterdam Pharma Company NV benefit from seasonalityJuly 2025 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Fed Meeting: Is NewAmsterdam Pharma Company NV Equity Warrant exposed to political riskPortfolio Return Summary & Daily Oversold Bounce Ideas - baoquankhu1.vn
Gains Report: What is the implied volatility of Drugs Made In America Acquisition Corp Equity RightWeekly Trade Analysis & AI Enhanced Execution Alerts - baoquankhu1.vn
First Week of March 20th Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq
Relative Strength Alert For NewAmsterdam Pharma Company - Nasdaq
Aug Action: Does NewAmsterdam Pharma Company NV Equity Warrant align with a passive investing strategy2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility - Yahoo Finance
Aug Rallies: How NewAmsterdam Pharma Company NV stock compares to market leadersPortfolio Update Summary & High Return Trade Guides - Bộ Nội Vụ
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech With 46% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in NAMS Response - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.5%Time to Sell? - MarketBeat
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress - TipRanks
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 - Investing.com
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma Updates on Obicetrapib Clinical Development and EMA Approval Timeline - Quiver Quantitative
Drug in late-stage tests cuts cholesterol and an Alzheimer’s marker - Stock Titan
Can NewAmsterdam Pharma Company N.V. stock continue upward trendModel Comparison & how to pick the right width - Улправда
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsJuly 2025 Selloffs & Reliable Volume Spike Alerts - ulpravda.ru
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities - The Manila Times
Can NewAmsterdam Pharma Company N.V. (KH6) stock hold up in economic slowdownMarket Activity Summary & AI Forecasted Entry and Exit Points - Улправда
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock near bottom after declineAnalyst Upgrade & Verified Chart Pattern Signals - ulpravda.ru
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from strong economy2025 Historical Comparison & Community Consensus Stock Picks - Улправда
What dividend safety score for NewAmsterdam Pharma Company N.V. stock2025 Technical Patterns & Low Risk High Reward Ideas - ulpravda.ru
Louise Frederika Kooij Sells 2,647 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 6,000 Shares of Stock - MarketBeat
Is NewAmsterdam Pharma Company N.V. stock positioned for long term growthEconomic Indicators Overview & Affordable Growth Investments - Улправда
A Look At NewAmsterdam Pharma (NAMS) Valuation As Late Stage CETP Trial Progress Draws Investor Attention - Sahm
NewAmsterdam Pharma (NAMS) Stock Analysis: Unveiling a 43.88% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 - Insider Monkey
NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners - Investing.com Canada
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.4%Time to Sell? - MarketBeat
NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS - TechStock²
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Behavioral Patterns of NAMS and Institutional Flows - Stock Traders Daily
ID Info Business Services Limited Enters Reversal Setup in Weekly ChartsEconomic Indicators Overview & Target Triple-Digit Stock Opportunities - earlytimes.in
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 26,011 Shares of Stock - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 75,117 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock - MarketBeat
Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
How (NAMSW) Movements Inform Risk Allocation Models - Stock Traders Daily
Is NewAmsterdam Pharma Company NV Equity Warrant a good long term investmentUtilities Sector Analysis & Identify Ideal Buy Points With Precision - Early Times
EBITDA per share of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView — Track All Markets
Operating cash flow per share of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView — Track All Markets
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):